STS Presentation. Executive Summary Huge market with high growth potential through right therapeutics areas focus  2 nd highest population in middle.

Slides:



Advertisements
Similar presentations
Healthcare Group. Vision To become the leading branded health related business in the Middle East and to be an outstanding business of integrity and inspiration.
Advertisements

Business Development Licensing Strategic Marketing HFA-Consulting.com Pharmaceutical Business Development & Licensing Consultancy HFA provides specialist.
Naveh Pharma Ltd. Innovative Healthcare Products Facts & Figures May 2006.
COMPANY PRESENTATION Kazakhstan 2012.
Perspectives on U.S. and Global Economy Houston Region Economic Outlook Houston Economics Club and Greater Houston Partnership Omni Houston Hotel December.
1 Presented by: Charalambos Orphanides Senior Commercial and Industrial Officer Ministry of Commerce, Industry & Tourism Republic Of Cyprus w ww.mcit.gov.cy/tsw.
RETAIL RUSSIA Conference > TOPICS: Why Russia? Market Entry Strategy Practical Advice - Russia Copyright © 2003 MarketOption, Inc. Presented by:With assistance.
Medical Tourism in Jordan Prepared by: Dr. Ratib Hinnawi (MOH Advisor) Ministry of Health – Jordan 2007.
An Overview of the Canadian Pharmaceutical Industry
Towards the Global Markets Merja Heikela Senior Consultant, Finpro UK-Benelux.
Female Managers and careers in Sweden Monica Renstig Women´s Business Research Institute One of the researchers/authors in SNS project “More women to the.
Ontario Labour Market Information Service Canada Ontario Region Research and Analysis May 2008.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Healthcare Reform in China and Its Impact on the Pharmaceutical Industry Hengpeng Zhu Institute of Economics Chinese Academy of Social Sciences
General people’s Committee for Health & Environement
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
1 The Swiss Chemical and Pharmaceutical Industry Zurich, April 2012.
Artem Dolzhenko MO-09. Companies with the developed trademark have significant advantages over other economic enterprises on the market. Using a well-known.
Case for Alignment. Should every one have a strategy? Vision Goals Constraints Time Money Competing forces You are not alone.
Pharmaceutical Industry Emerging Opportunities for Mobile Health TechNet Meeting June 2005.
An Overview of Scotland’s National Health Service Aziz Sheikh Professor of Primary Care Research & Development and Co-Director, Centre for Population Health.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Professor Song CHEN, Ph.D. Deputy Dean, School of Economics & Management Tongji University Oct. 7, 2013 The Changing National.
HEINEKEN International Making HIV programmes work The Heineken HIV programme- First ten years.
Facts and Figures 2008 Medicines and Health Care The Norwegian Association of Pharmaceutical Manufacturers (LMI)
“Implementing EU Acquis, Procedures and Challenges” Poland, Warsaw 22 nd –23 rd September 2004 Dr Annita Anastassiadou Co-ordinator EU Integration Sector.
SOMEDAY YOU WILL REAP WHAT YOU SOW India: The New Global Business Opportunity Arun Maira The Boston Consulting Group San Francisco.
Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February
The Department of Oncology Dr Adnan Ezzat Chairman, Department of Oncology King Faisal Specialist Hospital & Research Centre Healthcare System®
How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of.
September 10, 2014 Research Healthcare Environment.
The Pharmaceutical Industry in Turkey
 The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.  Pharmaceutical companies are.
“Mutual Cooperation to Common Success”. Company presentation FMS established on Previous pharmaceutical experience of staff since Triviumfarm.
The Company History & main achievements  2006: Sopharma Trading evolved by merger of 5 distributors  Largest Bulgarian Companies Capital Top 100: o.
The Company History & Main Achievements  2006: Sopharma Trading evolved by merger of 5 distributors  Largest Bulgarian companies Capital Top 100: o.
ACCESS TO MEDICINES - POLICY AND ISSUES
Factors that Contribute to the Selection of Products/Services in Small Business.
By: Zachary Nunn. Aflac History John, Paul and William Amos Founded in 1955 in Columbus, Georgia Originally named American Family Life Insurance Company.
Abt Associates Inc. SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global.
Objective The aim was to assess purchasing pharmaceuticals in the public health sector in Jordan through the joint procurement for participating parties.
1 The impact of Off Patents on the Supply Chain Mark James UKMANAGING DIRECTOR.
Elizabeth Duhamel Whitney Smyth.  What country do you think is China’s biggest exporter?
Healthcare equipment market A short review. 10 years later 2005, I came back 10 years after I left Turkey 1995 –Large public market – small private –Focus.
China Bottled Mineral Water Market
India: Gains & Growth Pains What Experts from India have to say.
BUY PACKET AON (AON). THESIS Aon plc (Aon) is a global provider of risk management services, insurance and reinsurance brokerage, and human resource consulting.
State Prescription Drug Purchases. Pricing Standards. Initiative Statute. Jeffrey S. Hoch, PhD Professor, Department of Public Health Sciences Associate.
Al Noor Drug Store Amman- Jordan Established in 2001.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Allergy Drugs Markets in China Published on : Jun 2014.
 Cardinal Health, Inc. Dublin, OH United States  SUZUKEN CO., LTD. Nagoya Japan  Takeda Pharmaceutical Company Limited Osaka Japan.
World Offshore Maintenance, Modifications & Operations Market Forecast World Offshore Maintenance, Modifications & Operations Market Forecast.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Iran’s Automotive Industry: Opportunities & Challenges ahead
Developing and Broadening Specialists in Research & Development
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
Petrochemical Opportunities
MarketsandMarkets Presents U.S. will hold the leadership in the global Oncology Information System Market
MarketsandMarkets Presents Global Oncology Information System Market Share Analysis, By Key Players & Competitive Scenario
Healthcare PPP Opportunities in the Kingdom of Bahrain
Christine Hamilton Deputy Director, UKTI West Midlands
Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.
AllStar Marketing Plan
Bertelsmann Education Strategy
Unit -1.
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

STS Presentation

Executive Summary Huge market with high growth potential through right therapeutics areas focus  2 nd highest population in middle east after Egypt, 18 th in the world and ranked 94 th in growth rate worldwide  Iran is the 3 rd biggest Pharma market in the middle east after KSA and turkey  Political situation and sanctions is expected to be lifted in early  Reimbursement covers 83% of the population with co-pay of 30% to medicines.  Pharmaceutical market growing at a CAGR of 18% by value in € during 2009 till 2012 and Iran is ranked 3 rd pharmaceutical sales in meta region after turkey and KSA with $3.20 Bn in  Market growth is expected to continue but in slower rate ( approx. 12% to 15% till 2020).  Imported products contribute to 3% by volume and 37% by value while top 10 products by value are all specialty products and they contribute to 8% of the market. I.E. New launched products in diabetes, cancer., Etc.  The use of locally produced generics is widespread, especially in the governmental sector where Iran is mainly a generics market but with high brand loyalty among specialists and people.  Foreign players are enhanced to get to licensing agreements with local manufacturers since government & MOH support local production.  Successful MNCS are adopting different import and a focused therapeutic area strategy with localization as an important arm to allow registration and better pricing with a lesser custom tariff

Macroeconomics & sociopolitical situation  POPULATION (MIN) (2015 EST.) 84  POPULATION GROWTH RATE (2015 EST.) 1.24  BIRTH RATE / 1,000 POPULATION (2015 EST.) 1.5K  DEATH RATE / 1,000 POPULATION (2015 EST.) 400K  URBAN POPULATION 71%  LIFE EXPECTANCY YEARS 75  SINGLE MOTHERS FAMILY 9.5%  OIL EXPORT / MILLION BARREL / DAY 2.2  GDP PER CAPITA ($)(2014) 4751  INFLATION RATE (CONSUMER PRICES) 24%  LITERATURE RATE 85%  UNEMPLOYMENT RATE(2015) 19%  HEALTHCARE EXPENDITURE AS % OH GDP 7.8%  GOVERNMENT HEALTHCARE EXPENDITURE, US BN.(2014) 11.3  PRIVATE HEALTHCARE EXPENDITURE,US BN.(2014) 20  NUMBER OF PHYSICIANS /1000 POPULATION 0.89  NUMBER OF HOSPITALS BEDS / 1000 POPULATION 1.7

Potential market / Hospital TypeNumber % Educational University22 Medical University41 Social Security8 Armed Force5.5 Charity3.5 Private16.5 Oil1 Others2.5 Treatment CentersNumber Medical Centers47161 Dental Centers8647 Pharmacy Centers6305 Laboratory Sciences950 From The Total Hospital Number Of 1176

Members of SHAFAYAB Group Shafayab Gostar Shafayab Farda Shafayab Distributer Modava Saayaan Tadbir Dr. Hamid Khoe Managing director Tehran university professor Member of board of directors at Iran Medical Council Head of Iran Pharmacists’ Scientific Association Former head of Tehran University chain of Pharmacies Dr.Sobhanian Hold a PH.D degree in Anticancer drugs from the UK CEO and Managing director of Shafa yab group university lecturer at Azad Pharmacy University in Tehran. Member of board of directors at Pharmacists’ Scientific association Dr.Morteza Azarnoosh Managing director Former Deputy minister of health and head of Iran FDO Former Director of TPICO holding 35% of total Pharma market in Iran. Former Director of Pasteur Institute of Iran Former Director of Alborz Darou Dr. Hamid Salavati Managing director Former commercial deputy of Hejrat Distribution Co Dr.Maysam Karbalaie Managing director former commercial of Safir Co. Head developer of SQOURENT educational platform Senior consulting software Eng. at Hematogenix

Shafayab Group Was founded in 2001 Located in Beheshti Ave. Tehran Top ranking importer of ethical / OTC pharmaceuticals and health care products Represent 15 internationally well-known pharmaceutical companies Was founded in 1999 Drugs and Druggists' Sundries Merchant Wholesalers Emergency importation Was founded in 2006 One of top ten pharmaceutical distributer of Iran Having agency in 20 cities to guarantee prompt and continuous supply Was founded in 1962 located around 80 km west of Tehran total area of the site is 10,000 m2 holds 45 production licenses Around 90 employees currently has an agreement with Novartis, Boehringer and Actavis Was founded in 2015 Representative of dental products in Iran our elite group is collected from well-known Iranian companies Shafayab Gostar Shafayab Farda Shafayab Distributer Modava Saayaan Tadbir

Shafayab Gostar Agencies

Competition Manufacturer Market Share

Most Selling 3M’s Product In Iran

STRENGTH /OPPORTUNITY  THIS SUPERIORITY HAS BEEN REINFORCED VIA  HIGH EDUCATED AND UP-TO-DATE MANAGEMENT AND ENGINEERS THAT WORK BY TOGETHER TO GAIN THE COMPANY TARGET.  WORKING WITH HIGH QUALITY PRODUCT,  WELL KNOWN COMPANIES,  LOYALTY CLIENTS AND DOCTORS THAT TRUSTED TO OUR COMPANY AND MADE A DEAL WITH US BEFORE.  SUPPORTIVE RELATION WITH MOH AND SOCIAL SECURITY ORG.  DIFFERENT TALENTED MEMBERS OF SALES TEAMS  SALES AND ADVERTISING GROUP TO MAKE UNIQUE ADVERTISEMENT THUS, HIGH PRODUCTIVE OVERSEA COMPANIES TRUSTED, PREFER AND MAKE A DEAL WITH OUR COMPANY AS EXCLUSIVE AGENT

VISION  INVEST IN DIFFERENT LINES UNDER LICENSE MANUFACTURING  NEGOTIATE WITH PRINCIPLES AND SECURE EXPORT OF INTERNATIONAL PRODUCTS  IMPORT DIFFERENT LINES OF DENTIST PRODUCT TO MEET ALL THEIR MAIN REQUIREMENT  AT LEAST ONE OF OUR SOLD PRODUCT SHOULD BE AT ANY CLINIQUE OR HOSPITALS  OUR COMPANY HAS ABILITIES FOR SUPPLIED AND MANAGE IMPORTANT AREA SO WE ARE GOING TO COVER ALL MIDDLE EAST COUNTRIES